U.S. Markets open in 1 hr 45 mins
  • S&P Futures

    4,108.00
    -12.25 (-0.30%)
     
  • Dow Futures

    33,502.00
    -129.00 (-0.38%)
     
  • Nasdaq Futures

    13,798.25
    -10.50 (-0.08%)
     
  • Russell 2000 Futures

    2,218.20
    -12.40 (-0.56%)
     
  • Crude Oil

    59.96
    +0.26 (+0.44%)
     
  • Gold

    1,727.90
    -4.80 (-0.28%)
     
  • Silver

    24.99
    +0.12 (+0.49%)
     
  • EUR/USD

    1.1896
    -0.0021 (-0.1784%)
     
  • 10-Yr Bond

    1.6750
    0.0000 (0.00%)
     
  • Vix

    17.39
    +0.70 (+4.19%)
     
  • GBP/USD

    1.3724
    -0.0018 (-0.1290%)
     
  • USD/JPY

    109.3970
    +0.0210 (+0.0192%)
     
  • BTC-USD

    63,053.18
    +3,267.84 (+5.47%)
     
  • CMC Crypto 200

    1,337.40
    +42.81 (+3.31%)
     
  • FTSE 100

    6,874.04
    -15.08 (-0.22%)
     
  • Nikkei 225

    29,751.61
    +212.88 (+0.72%)
     

Sunesis Pharma Climbs After Viracta Poised To Nab US Patent For Nanatinostat/Valganciclovir Regime

Vandana Singh
·1 min read
  • Sunesis Pharmaceuticals Inc (NASDAQ: SNSS) merger partner, Viracta Therapeutics Inc announces that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," related to the use of Viracta's oral combination product candidate of nanatinostat and valganciclovir.

  • The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial to treat Epstein-Barr virus (EBV)-associated lymphoma and other lymphoproliferative disorders. Upon its grant, the resulting patent will provide protection into at least 2040.

  • In November last year, Sunesis Pharmaceuticals announced to merge with Viracta Therapeutics in an all-stock deal.

  • Price Action: SNSS gained 5.5% at $3.49 in market trading hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.